Donepezil

Donepezil is a medication primarily used in the management of Alzheimer's disease, a progressive neurodegenerative disorder. It functions as a reversible acetylcholinesterase inhibitor, increasing levels of the neurotransmitter acetylcholine in the brain to mitigate cognitive decline. The drug is marketed globally under brand names such as Aricept and is a cornerstone of symptomatic treatment for dementia.

Medical uses

Donepezil is indicated for the symptomatic treatment of mild, moderate, and severe Alzheimer's disease, as confirmed by diagnostic criteria like those from the National Institute on Aging. It is also prescribed for dementia associated with Parkinson's disease. Clinical trials, such as those published in the Lancet, have demonstrated its efficacy in improving cognitive function and global clinical state as measured by scales like the Alzheimer's Disease Assessment Scale and the Clinical Global Impression of Change. Treatment is typically initiated and monitored by specialists in geriatrics or neurology.

Adverse effects

Common adverse effects are often cholinergic in nature and include nausea, diarrhea, insomnia, muscle cramps, fatigue, and vomiting. More serious potential effects involve bradycardia, syncope, and seizures, particularly in patients with underlying cardiac conduction abnormalities. The Food and Drug Administration has issued warnings regarding potential neuroleptic malignant syndrome and rhabdomyolysis. Drug interactions, particularly with other cholinergic agents or medications affecting the cytochrome P450 system like ketoconazole, can increase these risks.

Pharmacology

Donepezil acts as a selective, reversible inhibitor of acetylcholinesterase, the enzyme responsible for breaking down acetylcholine in the synaptic cleft. This action elevates acetylcholine concentration, facilitating neurotransmission in regions like the cerebral cortex and hippocampus that are critical for memory and are degenerated in Alzheimer's disease. It is metabolized primarily in the liver via the CYP2D6 and CYP3A4 isoenzymes and has a long elimination half-life, allowing for once-daily dosing. Its pharmacokinetics are linear, and it is highly bound to plasma proteins.

History

Donepezil was developed in the 1980s by researchers at the Japanese company Eisai Co., Ltd.. Its development was part of a broader scientific effort targeting the cholinergic hypothesis of Alzheimer's disease. It received approval from the Food and Drug Administration in 1996, following successful Phase III clinical trials. Subsequent approvals were granted by agencies like the European Medicines Agency and the Therapeutic Goods Administration. The drug's patent expiration led to the introduction of generic versions by companies such as Teva Pharmaceutical Industries.

Society and culture

Donepezil is listed on the World Health Organization's List of Essential Medicines. It has been the subject of significant health economic analyses by bodies like the National Institute for Health and Care Excellence regarding its cost-effectiveness in public health systems such as the National Health Service. The drug has appeared in popular media, including the film Still Alice, highlighting the societal impact of Alzheimer's disease. Its development and sales have had a substantial economic impact on Eisai Co., Ltd. and its licensing partner Pfizer.

Category:Drugs